Endometrial Cancer Advances – Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared a post on LinkedIn:
“For the past decade, new cases of endometrial (uterine) cancer have been on the rise in the United States, making it the leading cause of death among gynecologic cancers. The reasons for the steady rise in diagnoses and an increase in a subset of endometrial cancers known as ‘non-endometrioid’ are unclear.
But what is known is that these cancers have a wide array of genetic abnormalities and are often aggressive. With a decrease in federal research funding, the need for novel therapies is critical.
Despite this, there has been a more promising rise over the last few years: A new generation of drugs and drug combinations that are improving the outlook for patients with the disease.
Dana-Farber scientists are tackling the disease from multiple angles – hormonal therapy, immunotherapy, antibody-drug conjugates, and replication stress – to propel this promising new generation of therapies forward.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023